Literature DB >> 11379663

Reduced baroreflex sensitivity and blunted endogenous nitric oxide synthesis precede the development of hypertension in TGR(mREN2)27 rats.

A Borgonio1, S Pummer, K Witte, B Lemmer.   

Abstract

Transgenic TGR(mREN2)27 (TGR) rats are an animal model of fulminant hypertension characterized by an inverse circadian blood pressure profile. The present study addressed the contribution of nitric oxide (NO) synthesis and baroreflex function to hypertension and the inverse blood pressure pattern. NO synthesis was measured at four different times of day indirectly by excretion of NO metabolites (NOx: NO2- and NO3-) in the urine of 5- and 11-week-old TGR and Sprague-Dawley (SPRD) controls. Blood pressure, heart rate, and motor activity were recorded in age-matched rats of both strains using an implantable telemetry system. Beat-to-beat recording of blood pressure and pulse interval was performed hourly in 6-week-old animals over 24 h. From these data, baroreflex sensitivity (BRS) was calculated by linear regression of spontaneous fluctuations of blood pressure and corresponding changes of pulse interval. Baroreflex sensitivity was lower in pre-hypertensive TGR rats than in SPRD rats, and the reduction was restricted to the daily resting period. In both strains, NOx excretion showed circadian rhythmicity, with peak values during the activity period at night. Interestingly, excretion of NOx was reduced during the resting period in 5-week-old TGR rats prior to the development of hypertension. Impairment of NO synthesis and baroreflex function precede the development of hypertension in TGR rats. The reduction of both parameters was restricted to the resting period and, therefore, could be involved in the development of the inverse circadian blood pressure profile of TGR rats.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11379663     DOI: 10.1081/cbi-100103187

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  7 in total

Review 1.  Angiotensin peptides and central autonomic regulation.

Authors:  Debra I Diz; Amy C Arnold; Manisha Nautiyal; Katsunori Isa; Hossam A Shaltout; E Ann Tallant
Journal:  Curr Opin Pharmacol       Date:  2011-02-28       Impact factor: 5.547

Review 2.  Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives.

Authors:  Shereeni J Veerasingham; Mohan K Raizada
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

3.  Angiotensin-(1-7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats.

Authors:  Debra I Diz; Maria Antonia Garcia-Espinosa; Patricia E Gallagher; Detlev Ganten; Carlos M Ferrario; David B Averill
Journal:  J Cardiovasc Pharmacol       Date:  2008-06       Impact factor: 3.105

4.  Baroreflex sensitivity varies during the rat estrous cycle: role of gonadal steroids.

Authors:  Robert K Goldman; Afaf S Azar; Julia M Mulvaney; Carmen Hinojosa-Laborde; Joseph R Haywood; Virginia L Brooks
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-03-04       Impact factor: 3.619

5.  Elevated resting blood pressure augments autonomic imbalance in posttraumatic stress disorder.

Authors:  Ida T Fonkoue; Seth D Norrholm; Paul J Marvar; Yunxiao Li; Melanie L Kankam; Barbara O Rothbaum; Jeanie Park
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-10-10       Impact factor: 3.619

6.  Basal and Activated Calcium Sensitization Mediated by RhoA/Rho Kinase Pathway in Rats with Genetic and Salt Hypertension.

Authors:  Michal Behuliak; Michal Bencze; Ivana Vaněčková; Jaroslav Kuneš; Josef Zicha
Journal:  Biomed Res Int       Date:  2017-01-19       Impact factor: 3.411

7.  Medullary Endocannabinoids Contribute to the Differential Resting Baroreflex Sensitivity in Rats with Altered Brain Renin-Angiotensin System Expression.

Authors:  Chris L Schaich; Megan Grabenauer; Brian F Thomas; Hossam A Shaltout; Patricia E Gallagher; Allyn C Howlett; Debra I Diz
Journal:  Front Physiol       Date:  2016-06-09       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.